Concern is often expressed about the possibility of reidentification of participants in dementia genetic studies. How big of a problem is that in reality? How does patient consent play into DNA sequences being monetized? What would an ideal publicly available data set look like? Find out what leading dementia researchers think about the trends in the field and what are their recommendations for the future. Panelists in the session: -Prof. Nick Fox, UKDRI, University College London -Dr. Valentia Escott-Price, UKDRI, University of Cardiff -Dr. Sobia Raza, PHG Foundation Session moderated by: Dr. Gabrielle Strobel, ALZ Forum For other videos and dementia research-related resources, visit ion.illumina.com/genetics-of-dementia-resource-library-yt For Research Use Only. Not for use in diagnostic procedures QB #6255 Subscribe to the Illumina video channel youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM